Natera (NTRA) Q2 2026 Earnings Call Transcript
Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.
How this was made
The 30-second read
Why it matters
Traders can update models using the raised full-year revenue guidance, improved gross margin, and ASP commentary for Signatera, while monitoring the stated expectation that Q3 will not repeat Q2’s volume strength.
Market read
The combination of raised guidance, strong test volume growth, and regulatory approval milestones is likely to drive near-term repricing, but management’s Q3 volume normalization note can cap upside.
What to watch
Revenue true-ups remain sizable ($52.3M) and SG&A is rising with clinical trial spend, so margin durability and reimbursement timing could be key swing factors.
Background
This is Natera’s Q2 2026 earnings call transcript, covering financial results, test volumes, reimbursement/coverage updates, and clinical study progress.
Ticker impact
Natera raised full-year revenue guidance to $2.85B-$2.91B and reported Q2 revenue of $752.8M, up 37.7% with higher volume and ASP.
Likely positive bias for the next session and into guidance digestion, with volatility risk around expectations for Q3 volume records.
The article contains multiple primary datapoints: raised revenue guidance, improved gross margin, and FDA and PMDA approval milestones for Signatera, partially offset by a caution that Q3 will not set a new volume record due to prior-quarter weather effects.
Market effects
Reinforces momentum in oncology MRD and prenatal testing reimbursement, potentially supporting sentiment for adjacent liquid biopsy and diagnostics peers.
Japan regulatory milestone (PMDA approval) may modestly improve cross-border adoption expectations for diagnostics providers.
FDA and PMDA companion diagnostic approvals strengthen the global commercialization narrative for MRD testing platforms.
Counterpoint
The guidance raise may already be priced in, and the Q3 volume caution suggests near-term growth could decelerate versus Q2’s weather-influenced comps.
Key entities
- companyNatera, Inc.
Reported Q2 2026 results and raised full-year revenue guidance; discussed Signatera and Panorama adoption, reimbursement, and clinical milestones.
- productSignatera
MRD test discussed as receiving US FDA approval as a companion diagnostic and Japanese PMDA approval.
- productPanorama
Enhanced prenatal test with a reported no-call rate of 0.5% and new account wins driving women’s health growth.
- clinical_studyFIND trial
Early cancer detection study with enrollment completion expected in Q3 2026.
